» Articles » PMID: 38291529

Potential Prognostic Determinants for FET::CREB Fusion-positive Intracranial Mesenchymal Tumor

Abstract

Intracranial mesenchymal tumor (IMT), FET::CREB fusion-positive is a provisional tumor type in the 2021 WHO classification of central nervous system tumors with limited information available. Herein, we describe five new IMT cases from four females and one male with three harboring an EWSR1::CREM fusion and two featuring an EWSR1::ATF1 fusion. Uniform manifold approximation and projection of DNA methylation array data placed two cases to the methylation class "IMT, subclass B", one to "meningioma-benign" and one to "meningioma-intermediate". A literature review identified 74 cases of IMTs (current five cases included) with a median age of 23 years (range 4-79 years) and a slight female predominance (female/male ratio = 1.55). Among the confirmed fusions, 25 (33.8%) featured an EWSR1::ATF1 fusion, 24 (32.4%) EWSR1::CREB1, 23 (31.1%) EWSR1::CREM, one (1.4%) FUS::CREM, and one (1.4%) EWSR1::CREB3L3. Among 66 patients with follow-up information available (median: 17 months; range: 1-158 months), 26 (39.4%) experienced progression/recurrences (median 10.5 months; range 0-120 months). Ultimately, three patients died of disease, all of whom underwent a subtotal resection for an EWSR1::ATF1 fusion-positive tumor. Outcome analysis revealed subtotal resection as an independent factor associated with a significantly shorter progression free survival (PFS; median: 12 months) compared with gross total resection (median: 60 months; p < 0.001). A younger age (< 14 years) was associated with a shorter PFS (median: 9 months) compared with an older age (median: 49 months; p < 0.05). Infratentorial location was associated with a shorter overall survival compared with supratentorial (p < 0.05). In addition, the EWSR1::ATF1 fusion appeared to be associated with a shorter overall survival compared with the other fusions (p < 0.05). In conclusion, IMT is a locally aggressive tumor with a high recurrence rate. Potential risk factors include subtotal resection, younger age, infratentorial location, and possibly EWSR1::ATF1 fusion. Larger case series are needed to better define prognostic determinants in these tumors.

Citing Articles

Expanding the spectrum of FUS::CREM-rearranged neoplasms: a case of mesenchymal malignant tumor with neuroendocrine differentiation.

Bani M, Suybeng V, Valent A, Faron M, Moog S, Al-Ghuzlan A Virchows Arch. 2025; .

PMID: 39984759 DOI: 10.1007/s00428-025-04061-1.


Malignant Epithelioid Mesenchymal Neoplasm with FUS::CREM Gene Fusion Arising in the Tongue: A Case Report Detailing Clinicopathological, Imaging, and Molecular Features.

Suaiti L, Faquin W, Dias-Santagata D, Deschler D, Juliano A, Sadow P Head Neck Pathol. 2024; 18(1):70.

PMID: 39102073 PMC: 11300739. DOI: 10.1007/s12105-024-01681-y.

References
1.
Aryee M, Jaffe A, Corrada-Bravo H, Ladd-Acosta C, Feinberg A, Hansen K . Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014; 30(10):1363-9. PMC: 4016708. DOI: 10.1093/bioinformatics/btu049. View

2.
Tauziede-Espariat A, Sievers P, Larousserie F, Benzakoun J, Guillemot D, Pierron G . An integrative histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET:CREB-fused broadening the spectrum of tumor entities in comparison with their soft tissue counterparts. Brain Pathol. 2021; 32(1):e13010. PMC: 8713527. DOI: 10.1111/bpa.13010. View

3.
De Los Santos Y, Shin D, Malnik S, Rivera-Zengotita M, Tran D, Ghiaseddin A . Intracranial myxoid mesenchymal neoplasms with gene rearrangement: report of 2 midline cases with one demonstrating durable response to MET inhibitor monotherapy. Neurooncol Adv. 2021; 3(1):vdab016. PMC: 7954092. DOI: 10.1093/noajnl/vdab016. View

4.
Sloan E, Gupta R, Koelsche C, Chiang J, Villanueva-Meyer J, Alexandrescu S . Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. Brain Pathol. 2021; 32(4):e13037. PMC: 9245938. DOI: 10.1111/bpa.13037. View

5.
Bale T, Oviedo A, Kozakewich H, Giannini C, Davineni P, Ligon K . Intracranial myxoid mesenchymal tumors with EWSR1-CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity?. Brain Pathol. 2017; 28(2):183-191. PMC: 8028671. DOI: 10.1111/bpa.12504. View